armoneve 20 mg/10 mg tablete s produljenim oslobađanjem
mundipharma gesellschaft m.b.h., wiedner gurtel 13, turm 24, og 15, beč, austrija - oksikodonklorid naloksonklorid dihidrat - tableta s produljenim oslobađanjem - 20 mg + 10 mg - urbroj: jedna tableta s produljenim oslobađanjem sadrži 20 mg oksikodonklorida, što odgovara 18 mg oksikodona i 10 mg naloksonklorida kao 10,9 mg naloksonklorid dihidrata, što odgovara 9 mg naloksona
armoneve 40 mg/20 mg tablete s produljenim oslobađanjem
mundipharma gesellschaft m.b.h., wiedner gurtel 13, turm 24, og 15, beč, austrija - oksikodonklorid naloksonklorid dihidrat - tableta s produljenim oslobađanjem - 40 mg + 20 mg - urbroj: jedna tableta s produljenim oslobađanjem sadrži 40 mg oksikodonklorida, što odgovara 36 mg oksikodona i 20 mg naloksonklorida kao 21,8 mg naloksonklorid dihidrata, što odgovara 18 mg naloksona
armoneve 5 mg/2,5 mg tablete s produljenim oslobađanjem
mundipharma gesellschaft m.b.h., wiedner gurtel 13, turm 24, og 15, beč, austrija - oksikodonklorid naloksonklorid dihidrat - tableta s produljenim oslobađanjem - 5 mg + 2,5 mg - urbroj: jedna tableta s produljenim oslobađanjem sadrži 5 mg oksikodonklorida, što odgovara 4,5 mg oksikodona i 2,5 mg naloksonklorida kao 2,73 mg naloksonklorid dihidrata, što odgovara 2,25 mg naloksona
targinact 5 mg/2,5 mg tablete s produljenim oslobađanjem
mundipharma gesellschaft m.b.h., wiedner gurtel 13, turm 24, og 15, beč, austrija - oksikodonklorid naloksonklorid dihidrat - tableta s produljenim oslobađanjem - 5 mg + 2,5 mg - urbroj: jedna tableta s produljenim oslobađanjem sadrži 5 mg oksikodonklorida, što odgovara 4,5 mg oksikodona, 2,73 mg naloksonklorid dihidrata, što odgovara 2,5 mg naloksonklorida i 2,25 mg naloksona
flutiform 125 mikrograma/5 mikrograma po potisku, stlačeni inhalat, suspenzija
mundipharma gesellschaft m.b.h., wiedner gurtel 13, turm 24, og 15, beč, austrija - flutikazonpropionat formoterolfumarat dihidrat - stlačeni inhalat, suspenzija - 125 mikrograma/5 mikrograma - urbroj: jedna odmjerena doza (doza koja izlazi iz ventila) sadrži: 125 mikrograma flutikazonpropionata i 5 mikrograma formoterolfumarat dihidrata, što odgovara isporučenoj dozi (dozi koja se oslobađa iz aktivatora) od približno 115 mikrograma flutikazonpropionata i 4,5 mikrograma formoterolfumarat dihidrata.
flutiform 250 mikrograma/10 mikrograma po potisku, stlačeni inhalat, suspenzija
mundipharma gesellschaft m.b.h., wiedner gurtel 13, turm 24, og 15, beč, austrija - flutikazonpropionat formoterolfumarat dihidrat - stlačeni inhalat, suspenzija - 250 mikrograma/10 mikrograma - urbroj: jedna odmjerena doza (doza koja izlazi iz ventila) sadrži: 250 mikrograma flutikazonpropionata i 10 mikrograma formoterolfumarat dihidrata, što odgovara isporučenoj dozi (dozi koja se oslobađa iz aktivatora) od približno 230 mikrograma flutikazonpropionata i 9 mikrograma formoterolfumarat dihidrata.
flutiform 50 mikrograma/5 mikrograma po potisku, stlačeni inhalat, suspenzija
mundipharma gesellschaft m.b.h., wiedner gurtel 13, turm 24, og 15, beč, austrija - flutikazonpropionat formoterolfumarat dihidrat - stlačeni inhalat, suspenzija - 50 mikrograma/5 mikrograma - urbroj: jedna odmjerena doza (doza koja izlazi iz ventila) sadrži: 50 mikrograma flutikazonpropionata i 5 mikrograma formoterolfumarat dihidrata, što odgovara isporučenoj dozi (dozi koja se oslobađa iz aktivatora) od približno 46 mikrograma flutikazonpropionata i 4,5 mikrograma formoterolfumarat dihidrata
evrysdi
roche registration gmbh - risdiplam - mišićna atrofija, kralješnica - ostali lijekovi za poremećaje mišićno-koštanog sustava - evrysdi is indicated for the treatment of 5q spinal muscular atrophy (sma) in patients with a clinical diagnosis of sma type 1, type 2 or type 3 or with one to four smn2 copies.
esbriet
roche registration gmbh - pirfenidone - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - imunosupresivi - esbriet is indicated in adults for the treatment of idiopathic pulmonary fibrosis.
comirnaty
biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - cjepiva - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama.